Dyne Therapeutics Inc - Asset Resilience Ratio

Latest as of March 2026: 20.28%

Dyne Therapeutics Inc (DYN) has an Asset Resilience Ratio of 20.28% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See DYN working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

$219.05 Million

Cash + Short-term Investments

Total Assets

$1.08 Billion

All company assets

Resilience Assessment

Good

Financial Resilience Level

Asset Resilience Ratio Trend (2007–2025)

This chart shows how Dyne Therapeutics Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see total assets of Dyne Therapeutics Inc.

Liquid Assets Composition Over Time

This chart breaks down Dyne Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore how much of Dyne Therapeutics Inc's assets are long-term investments to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	$0.00	0%
Short-term Investments	$219.05 Million	20.28%
Total Liquid Assets	$219.05 Million	20.28%

Asset Resilience Insights

Good Liquidity Position: Dyne Therapeutics Inc maintains a healthy 20.28% of assets in liquid form.
This level provides good financial flexibility while maintaining productive asset deployment.
The company has significant short-term investments, indicating active treasury management.

Dyne Therapeutics Inc Industry Peers by Asset Resilience Ratio

Compare Dyne Therapeutics Inc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
argenx NV ADR NASDAQ:ARGX	Biotechnology	15.95%
Madrigal Pharmaceuticals Inc NASDAQ:MDGL	Biotechnology	62.31%
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	Biotechnology	2.03%
Halozyme Therapeutics Inc NASDAQ:HALO	Biotechnology	12.71%
Tubize-Fin BR:TUB	Biotechnology	2.50%
Aurinia Pharmaceuticals Inc NASDAQ:AUPH	Biotechnology	33.23%
Nanobiotix NASDAQ:NBTX	Biotechnology	4.71%
Innovita Biological Technology Co. Ltd. A SHG:688253	Biotechnology	65.12%

Annual Asset Resilience Ratio for Dyne Therapeutics Inc (2007–2025)

The table below shows the annual Asset Resilience Ratio data for Dyne Therapeutics Inc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	18.30%	$217.19 Million	$1.19 Billion	-11.62pp
2024-12-31	29.92%	$206.82 Million	$691.23 Million	+29.03pp
2023-12-31	0.89%	$1.47 Million	$165.08 Million	-26.48pp
2022-12-31	27.38%	$83.86 Million	$306.32 Million	-13.91pp
2021-12-31	41.29%	$175.75 Million	$425.66 Million	+28.70pp
2020-12-31	12.58%	$44.46 Million	$353.33 Million	+12.31pp
2017-12-31	0.27%	$32.00 Million	$11.77 Billion	-0.72pp
2016-12-31	1.00%	$130.00 Million	$13.05 Billion	+0.13pp
2015-12-31	0.87%	$100.00 Million	$11.54 Billion	+0.17pp
2014-12-31	0.69%	$78.00 Million	$11.23 Billion	+0.22pp
2013-12-31	0.47%	$25.00 Million	$5.29 Billion	+0.19pp
2012-12-31	0.29%	$13.00 Million	$4.54 Billion	-1.39pp
2011-12-31	1.67%	$69.00 Million	$4.13 Billion	+0.61pp
2010-12-31	1.06%	$106.00 Million	$10.01 Billion	+0.35pp
2009-12-31	0.71%	$78.00 Million	$10.95 Billion	+0.10pp
2008-12-31	0.61%	$87.00 Million	$14.21 Billion	-0.17pp
2007-12-31	0.79%	$104.00 Million	$13.22 Billion	--

pp = percentage points

About Dyne Therapeutics Inc

NASDAQ:DYN USA Biotechnology

Market Cap

$2.96 Billion

Market Cap Rank

#4968 Global

#1672 in USA

Share Price

$17.90

Change (1 day)

-3.35%

52-Week Range

$12.37 - $26.78

All Time High

$47.04